1-4 of 4
Sijie Tang
Close
Sort by
Journal Articles

The Promising Third-Generation TKI Olverembatinib in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed/Refractory Disease

Weiyang Liu, Cheng Wang, Sijie Tang, Jiayi Ren, Lijun Peng, Yongmei Zhu, Xiangqin Weng, Wanyan Ouyang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jin Wang, Jian-Qing Mi
Journal: Blood
Blood (2023) 142 (Supplement 1): 5902.
https://doi.org/10.1182/blood-2023-188733
Published: 2023
Journal Articles

Dose Escalation of Blinatumomab Is a Better Option for MRD-Positive CR Patients, Results from a Single-Center Real World Study of Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in China

Sijie Tang, Jiayi Ren, Weiyang Liu, Xiangqin Weng, Yongmei Zhu, Cheng Wang, Lijun Peng, Wenqian Xu, Yuxuan Shang, Wenyan Yu, Jiaojiao Zhang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jian-Qing Mi, Jin Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5885.
https://doi.org/10.1182/blood-2023-189703
Published: 2023
Journal Articles

A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia in Adults: Updated Results from RJ-ALL2020.2A Trial

Weiyang Liu, Cheng Wang, Sijie Tang, Jiayi Ren, Lijun Peng, Yongmei Zhu, Xiangqin Weng, Wanyan Ouyang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jian-Qing Mi, Jin Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5880.
https://doi.org/10.1182/blood-2023-180326
Published: 2023
Journal Articles

The Prognostic Significance of 1-Year Persistent MRD Negativity in Chinese ALL Patients: 5-Year Follow-up Results from RJ-ALL 2014 Trial

Jiayi Ren, Sijie Tang, Weiyang Liu, Xiangqin Weng, Cheng Wang, Lijun Peng, Wenqian Xu, Yuxuan Shang, Jie Hao, Wenyan Yu, Jiaojiao Zhang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jin Wang, Jian-Qing Mi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6057.
https://doi.org/10.1182/blood-2023-189710
Published: 2023